MORE Trial: Raloxifene and Vertebral Fracture Risk
JAMA (1999)
Reduced vertebral fracture risk by 30 to 50% over 3 years in 7,705 postmenopausal women.
Raloxifene
Oral tablet (60mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
hormones
RaloxifeneRaloxifene
Second-generation SERM acting as estrogen agonist in bone and antagonist in breast/uterine tissue. FDA-approved for postmenopausal osteoporosis and breast cancer risk reduction. Used in men for gynecomastia management.
Reduces vertebral fracture risk
Reduces invasive breast cancer risk ~50%
Does not stimulate endometrium (safer than tamoxifen)
Favorable lipid effects (reduces LDL)
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Binds ERα and ERβ, recruiting different coactivator complexes depending on tissue. In bone, mimics estrogen's anti-resorptive effect. In breast and uterine tissue, blocks estrogenic stimulation. Does not stimulate endometrium.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Raloxifene.
STAR Trial: Raloxifene vs Tamoxifen for Breast Cancer Prevention
JAMA (2006)
As effective as tamoxifen in reducing invasive breast cancer with fewer uterine cancers and thromboembolic events.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Hot flashes
- Leg cramps
- Peripheral edema
Less common but serious risks
- VTE (DVT, PE)
- Fatal stroke risk (RUTH trial in high CV risk women)
Generally not appropriate for
- Active or history of VTE
- Pregnancy
- Premenopausal women
Typical monitoring
- Bone mineral density (DXA)
- Lipid panel
- Thrombotic symptom review
FAQ
Quick answers.
Second-generation SERM acting as estrogen agonist in bone and antagonist in breast/uterine tissue. FDA-approved for postmenopausal osteoporosis and breast cancer risk reduction. Used in men for gynecomastia management.
Reduces vertebral fracture risk. Reduces invasive breast cancer risk ~50%. Does not stimulate endometrium (safer than tamoxifen). Favorable lipid effects (reduces LDL).
Common side effects include: hot flashes, leg cramps, peripheral edema. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Second-generation SERM acting as estrogen agonist in bone and antagonist in breast/uterine tissue. FDA-approved for postmenopausal osteoporosis and breast cancer risk reduction. Used in men for gynecomastia management.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.